The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin to processes for preparation thereof to the use thereof for treatment and/or prevention of diseases and to the use thereof for producing medicaments for treatment and/or prevention of diseases especially of cardiovascular edematous and/or inflammatory disorders.